The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence.
Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print].
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print].
Advance and stagnation in the treatment of patients with lymphoma and myeloma: analysis using population-based cancer registry data in Japan from 1993 to 2006.
Chihara D et al. Int J Cancer. 2015 Feb 18. doi: 10.1002/ijc.29477. [Epub ahead of print].
Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
Chawla SS et al. Eur J Haematol. 2015 Feb 16. doi: 10.1111/ejh.12534. [Epub ahead of print].
Has the time come to reevaluate prognostic factors and to rebuild staging systems for Multiple Myeloma?
Kyrtsonis MC et al. Eur J Haematol. 2015 Feb;94(2):95. doi: 10.1111/ejh.12429.
The use of novel agents in multiple myeloma patients with hepatic impairment.
Stansfield LC et al. Future Oncol. 2015 Feb;11(3):501-10. doi: 10.2217/fon.14.270.
Early mortality in multiple myeloma.
Costa LJ et al. Leukemia. 2015 Feb 12. doi: 10.1038/leu.2015.33. [Epub ahead of print].
The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Hanaizi Z et al. Oncologist. 2015 Feb 11. pii: theoncologist.2014-0073. [Epub ahead of print].
The serological diagnostic challenges of multiple myeloma.
Gu Y et al. Br J Hosp Med (Lond). 2015 Feb;76(2):84-8. doi: 10.12968/hmed.2015.76.2.84.
Everything Points to Myeloma.
Gupta A et al. J Gen Intern Med. 2015 Feb 10. [Epub ahead of print].
Efficacy and outcome of allogeneic transplantation in IgD and non secretory myeloma. A report on behalf of themyeloma subcommittee of the Chronic Malignancies Working Party of the EBMT.
Morris C et al. Biol Blood Marrow Transplant. 2015 Feb 20. pii: S1083-8791(15)00119-6. doi: 10.1016/j.bbmt.2015.02.012. [Epub ahead of print].
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.
Baz R et al. Support Care Cancer. 2015 Feb 24. [Epub ahead of print].
Smoldering multiple myeloma: to treat or not to treat.
Gentile M et al. Expert Opin Pharmacother. 2015 Feb 8:1-6. [Epub ahead of print].
Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant.
Holstein SA et al. Biol Blood Marrow Transplant. 2015 Jan 31. pii: S1083-8791(14)01470-0. doi: 10.1016/j.bbmt.2014.12.026. [Epub ahead of print].
Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon.
Musto P et al. Leuk Lymphoma. 2015 Feb 4:1-9. [Epub ahead of print].
Variation in incidence and survival by ethnicity for patients with myeloma in England (2002-2008).
Samy EF et al. Leuk Lymphoma. 2015 Feb 4:1-21. [Epub ahead of print].
Socioeconomic Status is Independently Associated with Overall Survival in Patients with Multiple Myeloma.
Fiala MA et al. Leuk Lymphoma. 2015 Feb 4:1-29. [Epub ahead of print].
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Sheng Z et al. Hematol Oncol. 2015 Feb 3. doi: 10.1002/hon.2192. [Epub ahead of print].
Personalization of cancer treatment using predictive simulation.
Doudican NA et al. J Transl Med. 2015 Feb 1;13(1):43. [Epub ahead of print].
Bortezomib followed by autologous stem cell transplant for patients with hepatitis B positive multiple myeloma: a cautionary note.
Rund D et al. Leuk Lymphoma. 2015 Feb 19:1-2. [Epub ahead of print].
Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case-control study using electronic records.
Shephard EA et al. Br J Gen Pract. 2015 Feb;65(631):e106-13. doi: 10.3399/bjgp15X683545.